Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Jul 12;11(7):976.
doi: 10.3390/cancers11070976.

Locally Advanced Pancreatic Cancer: Work-Up, Staging, and Local Intervention Strategies

Affiliations
Review

Locally Advanced Pancreatic Cancer: Work-Up, Staging, and Local Intervention Strategies

Eran van Veldhuisen et al. Cancers (Basel). .

Abstract

Locally advanced pancreatic cancer (LAPC) has several definitions but essentially is a nonmetastasized pancreatic cancer, in which upfront resection is considered not beneficial due to extensive vascular involvement and consequent high chance of a nonradical resection. The introduction of FOLFIRINOX chemotherapy and gemcitabine-nab-paclitaxel (gem-nab) has had major implications for the management and outcome of patients with LAPC. After 4-6 months induction chemotherapy, the majority of patients have stable disease or even tumor-regression. Of these, 12 to 35% are successfully downstaged to resectable disease. Several studies have reported a 30-35 months overall survival after resection; although it currently remains unclear if this is a result of the resection or the good response to chemotherapy. Following chemotherapy, selection of patients for resection is difficult, as contrast-enhanced computed-tomography (CT) scan is unreliable in differentiating between viable tumor and fibrosis. In case a resection is not considered possible but stable disease is observed, local ablative techniques are being studied, such as irreversible electroporation, radiofrequency ablation, and stereotactic body radiation therapy. Pragmatic, multicenter, randomized studies will ultimately have to confirm the exact role of both surgical exploration and ablation in these patients. Since evidence-based guidelines for the management of LAPC are lacking, this review proposes a standardized approach for the treatment of LAPC based on the best available evidence.

Keywords: FOLFIRINOX; ablation; explorative laparotomy; locally advanced pancreatic cancer; resection.

PubMed Disclaimer

Conflict of interest statement

M.R.M. and K.P.v.L. are paid consultants for AngioDynamics®. The other authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

Figures

Figure 1
Figure 1
Overview of surgical procedure of LAPC after induction chemotherapy. * Since randomized studies confirming the efficacy of ablation in LAPC are lacking, patients should preferably be treated within the context of clinical trials; LAPC: locally advanced pancreatic cancer; PPPD: pylorus-preserved pancreatoduodenectomy; TP: total pancreatectomy; DP: distal pancreatectomy; IRE: irreversible electroporation; RFA: radiofrequency ablation.
Figure 2
Figure 2
Proposed work-up and treatment plan of LAPC. * Diagnostic laparoscopy can be performed either prior to the start of induction chemotherapy or prior to explorative laparotomy; ** Since randomized studies confirming the efficacy of ablation in LAPC are lacking, patients should only be treated within the context of clinical trials; BSC: best-supportive care; LAPC: locally advanced pancreatic cancer; (B)RPC: borderline resectable pancreatic cancer.

References

    1. Ferlay J., Soerjomataram I., Ervik M., Dikshit R., Eser S., Mathers C., Rebelo M., Parkin D.M., Forman D., Bray F. GLOBOCAN 2012 v1.1, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11. International Agency for Research on Cancer; Lyon, France: 2014.
    1. Siegel R.L., Miller K.D., Jemal A. Cancer statistics, 2015. CA Cancer J. Clin. 2015;65:5–29. doi: 10.3322/caac.21254. - DOI - PubMed
    1. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2013. CA Cancer J. Clin. 2013;63:11–30. doi: 10.3322/caac.21166. - DOI - PubMed
    1. Ducreux M., Cuhna A.S., Caramella C., Hollebecque A., Burtin P., Goere D., Seufferlein T., Haustermans K., Van Laethem J.L., Conroy T., et al. Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 2015;26(Suppl. 5):v56–v68. doi: 10.1093/annonc/mdv295. - DOI - PubMed
    1. Rombouts S.J., Mungroop T.H., Heilmann M.N., van Laarhoven H.W., Busch O.R., Molenaar I.Q., Besselink M.G., Wilmink J.W. FOLFIRINOX in Locally Advanced and Metastatic Pancreatic Cancer: A Single Centre Cohort Study. J. Cancer. 2016;7:1861–1866. doi: 10.7150/jca.16279. - DOI - PMC - PubMed